RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

Core Insights - RenovoRx has appointed Dr. Timothy Donahue, a distinguished UCLA surgeon and expert in pancreatic cancer, to its Scientific Advisory Board, enhancing the company's expertise in surgical oncology and translational research aimed at improving treatment strategies for complex cancers [1][5][6] Company Overview - RenovoRx, Inc. is a life sciences company focused on developing targeted oncology therapies and commercializing RenovoCath, an FDA-cleared drug-delivery device designed to address high unmet medical needs in cancer treatment [6][9] - The company's patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform aims to deliver therapeutic agents directly to tumor sites while minimizing systemic toxicity [6][9] Dr. Timothy Donahue's Role - Dr. Donahue is the Director of UCLA's Agi Hirshberg Center for Pancreatic Diseases and Chief of the Division of Surgical Oncology, bringing extensive clinical and research experience to RenovoRx [2][3] - His leadership in translational oncology and clinical research is expected to inform the development of localized therapies to improve patient outcomes [5][6] Research and Development - Dr. Donahue leads a National Institutes of Health-funded research laboratory focused on advancing treatment strategies for pancreatic cancer through mechanistic investigations [4] - RenovoRx is currently evaluating its intra-arterial gemcitabine product candidate (IAG) in the Phase III TIGeR-PaC trial, utilizing the RenovoCath device [7][8] Commercialization Efforts - RenovoRx has received its first commercial purchase orders for RenovoCath devices and is expanding its customer base, including high-volume National Cancer Institute-designated centers [9] - The company is exploring further revenue-generating activities to meet anticipated demand for its products [9]